Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)
• Treatments: Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• HIV Infected subjects

• Subjects failing in current HIV treatment, or

• Subjects with a viral load < 400 copies/mL and not tolerating their current HIV treatment.

Exclusion Criteria:

• Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit

• Subject is pregnant